Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: 10.1210/clinem/dgaa049
- Ereignis
-
Veröffentlichung
- (wo)
-
Aachen
- (wer)
-
Universitätsbibliothek der RWTH Aachen
- (wann)
-
2020
- Urheber
-
Johannsson, Gudmundur
Gordon, Murray B.
Højby Rasmussen, Michael
Håkonsson, Ida Holme
Karges, Wolfram
Sværke, Claus
Tahara, Shigeyuki
Takano, Koji
Biller, Beverly M. K.
- DOI
-
10.18154/RWTH-2020-04927
- URN
-
urn:nbn:de:101:1-2020111307351256274488
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Johannsson, Gudmundur
- Gordon, Murray B.
- Højby Rasmussen, Michael
- Håkonsson, Ida Holme
- Karges, Wolfram
- Sværke, Claus
- Tahara, Shigeyuki
- Takano, Koji
- Biller, Beverly M. K.
- Universitätsbibliothek der RWTH Aachen
Entstanden
- 2020
Ähnliche Objekte (12)
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany